Johnson & Johnson Executive Vice President Timothy Schmid executed a significant transaction involving the exercise of company stock options, as disclosed in a Form 4 filing with the U.S. Securities and Exchange Commission. The filing details that Schmid exercised options for 33,597 shares of Johnson & Johnson common stock. The transaction was executed on Friday, and the total value of the shares involved was $4,394,623.
At the time of the transaction, Johnson & Johnson shares were trading at $275.00, resulting in the total value mentioned above. The filing confirms that this transaction was a conversion of options, with the shares sold in the open market. Schmid is identified in the filing as an Executive Vice President at the company.
The article provides additional context regarding Johnson & Johnson's business structure. The company operates as the world's largest and most diverse healthcare firm, consisting of two divisions: innovative medicine and medtech. These divisions represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023.
Regarding the company's recent performance, the article notes that as of June 30, 2026, Johnson & Johnson achieved a revenue growth rate of approximately 6.6% over a three-month period. The company's debt-to-equity ratio is reported to be 0.58, which is below the industry average.
